secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001628280-24-021937
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma sells PRV for $105M, draws $20M from Hercules; cash runway extended into late 2025
--------------------------------------------------------------------------------

- Sold Rare Pediatric Disease Priority Review Voucher for $105M cash; buyer undisclosed.
- Drew additional $20M tranche under existing Hercules Capital term loan facility (interest-only until July 2027).
- Combined with $82M cash at March 31, 2024, total pro-forma cash ~$207M; runway extended into late 2025, excluding XOLREMDI sales.
- CFO Adam Mostafa awarded $102K discretionary bonus for efforts in securing the PRV sale.
- XOLREMDI (mavorixafor) received FDA approval in April 2024 for WHIM syndrome; Phase 3 trial in chronic neutropenia planned this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/0001628280-24-021937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024021937/xfor-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer